Literature DB >> 22878824

NCCN Clinical Practice Guidelines Acute myeloid leukemia.

Margaret R O'Donnell1, Camille N Abboud, Jessica Altman, Frederick R Appelbaum, Daniel A Arber, Eyal Attar, Uma Borate, Steven E Coutre, Lloyd E Damon, Salil Goorha, Jeffrey Lancet, Lori J Maness, Guido Marcucci, Michael M Millenson, Joseph O Moore, Farhad Ravandi, Paul J Shami, B Douglas Smith, Richard M Stone, Stephen A Strickland, Martin S Tallman, Eunice S Wang, Maoko Naganuma, Kristina M Gregory.   

Abstract

Acute myeloid leukemia (AML) remains the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for AML provide recommendations on the diagnostic evaluation and workup for AML, risk assessment based on cytogenetic and molecular features, treatment options for induction and consolidation therapies for younger and older (age ≥ 65 years) adult patients, and key supportive care considerations.

Entities:  

Mesh:

Year:  2012        PMID: 22878824     DOI: 10.6004/jnccn.2012.0103

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  91 in total

1.  Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission.

Authors:  Andrew M Brunner; Shuli Li; Amir T Fathi; Martha Wadleigh; Vincent T Ho; Kerry Collier; Christine Connolly; Karen K Ballen; Corey S Cutler; Bimalangshu R Dey; Areej El-Jawahri; Sarah Nikiforow; Steven L McAfee; John Koreth; Daniel J Deangelo; Edwin P Alyea; Joseph H Antin; Thomas R Spitzer; Richard M Stone; Robert J Soiffer; Yi-Bin Chen
Journal:  Br J Haematol       Date:  2016-07-19       Impact factor: 6.998

2.  FLT3-ITD with DNMT3A R882 double mutation is a poor prognostic factor in Chinese patients with acute myeloid leukemia after chemotherapy or allogeneic hematopoietic stem cell transplantation.

Authors:  Shanhao Tang; Hongjie Shen; Xinliang Mao; Haiping Dai; Xiaming Zhu; Shengli Xue; Zixuan Ding; Jing Lu; Depei Wu; Xiaowen Tang
Journal:  Int J Hematol       Date:  2017-06-14       Impact factor: 2.490

3.  Prognostic value of the expression of phosphatase and tensin homolog and CD44 in elderly patients with refractory acute myeloid leukemia.

Authors:  Xiao Huang; Dongyun Li; Tiantian Li; B O Zhao; Xinyi Chen
Journal:  Oncol Lett       Date:  2015-05-06       Impact factor: 2.967

4.  Comprehensive analysis of factors impacting risks and outcomes of therapy-related myeloid neoplasms following breast cancer treatment.

Authors:  K Sevcikova; Z Zhuang; G Garcia-Manero; R H Alvarez; H M Kantarjian; M Mego; C Albarracin; G Tang; S S Strom; L J Medeiros; G N Hortobagyi; J M Reuben; J D Khoury
Journal:  Leukemia       Date:  2015-05-15       Impact factor: 11.528

5.  Low platelet count reduces subsequent complete remission rate despite marrow with <5% blasts after AML induction therapy.

Authors:  X Chen; L F Newell; H Xie; R B Walter; J M Pagel; V K Sandhu; P S Becker; P C Hendrie; J L Abkowitz; F R Appelbaum; E H Estey
Journal:  Leukemia       Date:  2015-02-04       Impact factor: 11.528

6.  Characteristics of Sweet Syndrome in patients with acute myeloid leukemia.

Authors:  Syed M Kazmi; Naveen Pemmaraju; Keyur P Patel; Philip R Cohen; Naval Daver; Kathy M Tran; Farhad Ravandi; Madeleine Duvic; Guillermo Garcia-Manero; Sherry Pierce; Aziz Nazha; Gautam Borthakur; Hagop Kantarjian; Jorge Cortes
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-12-24

7.  A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study.

Authors:  Sarah A Buckley; Mary-Elizabeth Percival; Megan Othus; Anna B Halpern; Emily M Huebner; Pamela S Becker; Carole Shaw; Mazyar Shadman; Roland B Walter; Elihu H Estey
Journal:  Leuk Lymphoma       Date:  2018-10-02

Review 8.  Decitabine: a review of its use in older patients with acute myeloid leukaemia.

Authors:  Monique P Curran
Journal:  Drugs Aging       Date:  2013-06       Impact factor: 3.923

9.  High-dose idarubicin plus busulfan as conditioning regimen to autologous stem cell transplantation: promising post-remission therapy for acute myeloid leukemia in first complete remission?

Authors:  Ming Hong; Kou-Rong Miao; Run Zhang; Hua Lu; Peng Liu; Wei Xu; Li-Juan Chen; Su-Jiang Zhang; Han-Xin Wu; Hong-Xia Qiu; Jian-Yong Li; Si-Xuan Qian
Journal:  Med Oncol       Date:  2014-05-07       Impact factor: 3.064

10.  End-of-life characteristics and palliative care provision for elderly patients suffering from acute myeloid leukemia.

Authors:  Hon-Wai Benjamin Cheng; Cho-Wing Li; Kwok-Ying Chan; Ho-Yan Au; Pan-Fong Chan; Yim-Ching Sin; Yan Szeto; Mau-Kwong Sham
Journal:  Support Care Cancer       Date:  2014-07-05       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.